相关实验视频

Updated: Jan 12, 2026

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads
07:59

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads

Published on: July 21, 2017

10.0K

一个为期两周的修改基因饮食对肥胖成年人循环脂蛋白子类GDF15和FGF21的影响

Nana Zhang1, Na Liu1, Guoxia Zhao1

  • 1Department of Endocrinology and Metabolism, Xijing Hospital of The Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.

Journal of translational medicine
|November 7, 2025
PubMed
概括

一种修改过的素饮食 (MKD) 干预导致肥胖个体显著减肥和改善身体组成. 饮食也改变了GDF15和FGF21的水平,表明了超出传统脂质比率的新型代谢效应.

关键词:
纤维细胞生长因子21 21增长差异化因子 15 15基因饮食是基因的饮食.脂蛋白子类 脂蛋白子类肥胖问题 肥胖问题

更多相关视频

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice08:06

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice

Published on: November 27, 2019

9.5K
Assessing Whole-Body Lipid-Handling Capacity in Mice07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.7K

相关概念视频

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
230
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
163
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
208
Metabolic States of the Body: Fasting and Starvation01:24

Metabolic States of the Body: Fasting and Starvation

During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
2.7K